MagGenome Technologies Pvt. Ltd. is an India-based startup in the field of nano-bio technology with a primary focus on developing magnetic nanoparticles based technologies for life science, chemical, pharmaceutical and engineering applications.
With its headquarters in Cochin, India, MagGenome began operations in 2014. It was incubated in SciGenom Labs for a period of one year and is now a registered independent company from 2015.
Products and services:
MagGenome has developed a patented magnetic nanoparticles-based technology that is technically proficient and industrially viable. One of their major initiatives is to develop nucleic acid extraction kits using the patented technology. The company has developed DNA extraction kits under the brand name “XpressDNA”.
The XpressDNA Tissue Mini Kit allows efficient and reliable extraction of genomic DNA from fresh, frozen and ethanol-preserved tissues without the need of centrifugation steps. It can extract the genomic DNA from 50-100 mg of tissue in less than one hour. The kit is optimized for a wide variety of tissue samples such as brain, heart, liver, muscle, rat tail, ethanol preserved fish tissues, etc. The kit has additional benefits like Standardized protocol for easy DNA extraction, High yields with minimum sample input and high-quality DNA for downstream applications. (Please refer to the video for detail procedure)
What is unique about your technology over existing ones?
Our technologies score over other existing products in terms of ease of use, higher efficiency, and robustness. For instance, the DNA recovery of XpressDNA tissue kit is 1.5 to 2 times higher than other column-based or micron bead-based kits from competitors. Similarly, the binding capacity of our XpressAffinity Protein A nanoparticles is 2 folds higher than the current market leader. This high binding capacity of our methods is by virtue of large surface area of our nanoparticles as we used naked or uncoated magnetic nanoparticles without any polymeric coating material. Using these magnetic nanoparticles also makes all our processes free from the use centrifugation steps and/or packed columns.
What are your upcoming products?
The immobilized affinity chromatography ligands such as Protein A, Protein G and Glutathione are branded as XpressAffinity product line. In the present year, MagGenome will be introducing its XpressDNA product line including DNA extraction kits for tissue/cell lines, plasmids and bacteria along with the XpressAffinity products including immobilized Protein A, Protein G and Glutathione.
What is your target market?
MagGenome is mainly serving research labs and life science/pharmaceutical industries. They are providing several products such as XpressDNA and XpressAffinity kits and services like antibody immobilization and enzyme immobilization to various research and industrial labs. Some of the technologies like Immobilized vaccines and enzymes, which are under development, are earmarked for technology transfer.
How has your start up journey been?
Most of the pipeline products are a result of academic research conducted over the years. As per them, MagGenome is a typical case of academic research being translated into a commercial venture. In the initial months itself, they filed various patents and published high-quality papers which not only helped them to have a strong IP protection over their products but also gave time to analyze commercial aspects of their technologies.
Their initial products were focused on key markets like Bio-molecule extraction and protein purification which helped them to enter fields like Next generation sequencing and biomarker based diagnostics. Currently, MagGenome is exploring other biological and engineering applications of magnetic nanoparticles where their products can provide simpler alternatives to existing products.
Major milestones achieved in your journey:
Apart from nucleic acid extraction kit, another major achievement in the first year of inception was patenting the novel technique for immobilizing proteins on bare nanoparticles without any loss of functional properties. Enzymes, antibodies, vaccines and other functional proteins were successfully immobilized using this method. Since January 2017, the company has started doing custom projects for various research labs and industries.
Sharing their thoughts on biotech ecosystem in India – This is the most conducive time for startups in India because of various reasons. The market is unprecedentedly open to new ideas, products and companies. Increasing interest of Investors, supportive government policies and strong existing IT infrastructure also considerably helps the Biotech/Healthcare startups to flourish. Recently, influx of skilled manpower coupled with availability of top class instrumentation and research facilities have fueled the growth of Indian biotech startups. Overall, the scenario looks promising and reflects good prospects for the future.